Preferred Label : delafloxacin;
MeSH note : a fluoroquinolone anti-infective agent;
CISMeF synonym : ABT 492; RX-3341;
MeSH synonym : 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic
acid; 3-quinolinecarboxylic acid, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-;
MeSH hyponym : ABT492; ABT-492;
MeSH CAS label : 3-quinolinecarboxylic acid, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-;
Is substance : O;
UNII : 6315412YVF;
Origin ID : C477891;
UMLS CUI : C2828290;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3224934/fr/quofenix
2020
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
delafloxacin
delafloxacin
anti-bacterial agents
acute disease
soft tissue infections
skin diseases, bacterial
Methicillin-Resistant staphylococcus aureus
staphylococcal infections
Methicillin resistant Staphylococcus aureus infection (disorder)
administration, oral
infusions, intravenous
quinolones
fluoroquinolones
---
https://www.ema.europa.eu/en/medicines/human/EPAR/quofenix
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
delafloxacin
delafloxacin
anti-bacterial agents
anti-bacterial agents
delafloxacin
adult
skin diseases, bacterial
infusions, intravenous
administration, oral
product surveillance, postmarketing
soft tissue infections
acute disease
aged
drug interactions
pregnancy
breast feeding
topoisomerase II inhibitors
DNA topoisomerase IV
drug evaluation, preclinical
quinolones
fluoroquinolones
quinolones
fluoroquinolones
---